These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22797188)

  • 1. Effect of risedronate on bone in renal transplant recipients.
    Coco M; Pullman J; Cohen HW; Lee S; Shapiro C; Solorzano C; Greenstein S; Glicklich D
    J Am Soc Nephrol; 2012 Aug; 23(8):1426-37. PubMed ID: 22797188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
    Hines SL; Mincey BA; Sloan JA; Thomas SP; Chottiner E; Loprinzi CL; Carlson MD; Atherton PJ; Salim M; Perez EA
    J Clin Oncol; 2009 Mar; 27(7):1047-53. PubMed ID: 19075260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
    Recker RR; Ste-Marie LG; Chavassieux P; McClung MR; Lundy MW
    Osteoporos Int; 2015 Jan; 26(1):327-37. PubMed ID: 25304456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC; Tong KH; To CH; Siu YP; Ma KM
    Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; Rubí S; Oppenheimer F
    Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study.
    Miller KK; Meenaghan E; Lawson EA; Misra M; Gleysteen S; Schoenfeld D; Herzog D; Klibanski A
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2081-8. PubMed ID: 21525157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
    Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
    Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG
    J Clin Oncol; 2008 Jun; 26(16):2644-52. PubMed ID: 18427147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
    Iwamoto J; Takeda T; Sato Y; Shen CL; Yeh JK
    Exp Anim; 2006 Oct; 55(5):457-66. PubMed ID: 17090962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Intern Med; 2008; 47(8):717-23. PubMed ID: 18421187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats.
    Iwamoto J; Takeda T; Sato Y; Yeh JK
    Exp Anim; 2007 Apr; 56(2):103-10. PubMed ID: 17460355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.
    Pepe J; Isidori AM; Falciano M; Iaiani G; Salotti A; Diacinti D; Del Fiacco R; Sbardella E; Cipriani C; Piemonte S; Raimo O; Biondi P; Biamonte F; Lenzi A; Minisola S
    Endocrine; 2014 Nov; 47(2):456-62. PubMed ID: 25104272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
    Geller JL; Hu B; Reed S; Mirocha J; Adams JS
    Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
    McClung MR; Miller PD; Brown JP; Zanchetta J; Bolognese MA; Benhamou CL; Balske A; Burgio DE; Sarley J; McCullough LK; Recker RR
    Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis.
    Haworth CS; Sharples L; Hughes V; Elkin SL; Hodson ME; Conway SP; Etherington C; Elborn JS; Rendall J; Wheaton E; Kadri E; Elliott J; Barker HC; Bearcroft PW; Hlaing T; Compston JE
    J Cyst Fibros; 2011 Dec; 10(6):470-6. PubMed ID: 21849264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
    Iwaniec UT; Samnegård E; Cullen DM; Kimmel DB
    Bone; 2001 Oct; 29(4):352-60. PubMed ID: 11595618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
    McClung MR; Balske A; Burgio DE; Wenderoth D; Recker RR
    Osteoporos Int; 2013 Jan; 24(1):301-10. PubMed ID: 23079690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.